XELIRINOX Regimen a Triple Combination of XELoda, IRINotecan and OXaliplatin in First-line Treatment of Metastatic Pancreatic Adenocarcinoma

摘要

FOLFIRINOX CT has shown notable responses in patients with metastatic PAC and has significantly improved prognosis. However, FOLFIRINOX is currently not frequently applied to all patients because of its high incidence of adverse events. Alternated XELIRINOX may be better for its acceptance in more patients' population. In this study, we evaluated the efficacy and safety of XELIRINOX in metastatic PAC. A total of 40 metastatic PAC patients were treated with XELIRINOX (Capcitabine substitute 5-FU, 75% Irinotecan dose and 100% Oxaliplatin dose) between January 2014 and January 2018 in our NCC. All 40 patients were evaluated with CR occur only in 2.5% (1/40) with an OAR of 35% (14/40). The frequent grade 3/4 adverse events are neutropenia (30%) and diarrhea (30%). No treatment-related death was observed. The median OS and median PFS is 10.5 months and 7.5 months, respectively. In conclusion, XELIRINOX had significantly improved tolerance with near similar efficacy to FOLFIRINOX. These findings may provide evidence for the use of XELIRINOX in more patient population with metastatic pancreatic adenocarcinoma.